NASDAQ:ZFGN - Zafgen Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $2.49 -0.05 (-1.97 %) (As of 05/19/2019 04:40 AM ET)Previous Close$2.49Today's Range$2.44 - $2.5552-Week Range$2.33 - $12.35Volume126,208 shsAverage Volume206,012 shsMarket Capitalization$92.95 millionP/E RatioN/ADividend YieldN/ABeta-0.45 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Zafgen, Inc., a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and other metabolically related disorders. The company's lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase 2 clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders. It also develops ZGN-1258, a MetAP2 inhibitor for treatment of PWS. Zafgen, Inc. was founded in 2005 and is headquartered in Boston, Massachusetts. Receive ZFGN News and Ratings via Email Sign-up to receive the latest news and ratings for ZFGN and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ZFGN Previous Symbol CUSIPN/A CIK1374690 Webwww.zafgen.com Phone617-622-4003Debt Debt-to-Equity Ratio0.17 Current Ratio7.83 Quick Ratio7.83Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.21 per share Price / Book1.13Profitability EPS (Most Recent Fiscal Year)($1.90) Net Income$-61,370,000.00 Net MarginsN/A Return on Equity-70.60% Return on Assets-52.76%Miscellaneous Employees38 Outstanding Shares37,330,000Market Cap$92.95 million Next Earnings Date8/6/2019 (Estimated) OptionableOptionable Zafgen (NASDAQ:ZFGN) Frequently Asked Questions What is Zafgen's stock symbol? Zafgen trades on the NASDAQ under the ticker symbol "ZFGN." How were Zafgen's earnings last quarter? Zafgen Inc (NASDAQ:ZFGN) released its quarterly earnings data on Thursday, May, 9th. The biopharmaceutical company reported ($0.35) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.40) by $0.05. View Zafgen's Earnings History. When is Zafgen's next earnings date? Zafgen is scheduled to release their next quarterly earnings announcement on Tuesday, August 6th 2019. View Earnings Estimates for Zafgen. What price target have analysts set for ZFGN? 7 equities research analysts have issued twelve-month price objectives for Zafgen's stock. Their forecasts range from $4.52 to $17.00. On average, they expect Zafgen's stock price to reach $8.3040 in the next year. This suggests a possible upside of 233.5% from the stock's current price. View Analyst Price Targets for Zafgen. What is the consensus analysts' recommendation for Zafgen? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zafgen in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zafgen. Has Zafgen been receiving favorable news coverage? News stories about ZFGN stock have been trending negative on Sunday, according to InfoTrie. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Zafgen earned a daily sentiment score of -2.1 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the near future. Who are some of Zafgen's key competitors? Some companies that are related to Zafgen include Sinovac Biotech (SVA), Innate Pharma (IPHYF), Abeona Therapeutics (ABEO), Rigel Pharmaceuticals (RIGL), Theratechnologies (THERF), AMAG Pharmaceuticals (AMAG), Keryx Biopharmaceuticals (KERX), AC Immune (ACIU), Beyondspring (BYSI), Kindred Biosciences (KIN), Xeris Pharmaceuticals (XERS), Merus (MRUS), Hookipa Pharma (HOOK), XBiotech (XBIT) and Five Prime Therapeutics (FPRX). What other stocks do shareholders of Zafgen own? Based on aggregate information from My MarketBeat watchlists, some companies that other Zafgen investors own include CA (CA), Endologix (ELGX), TG Therapeutics (TGTX), BlackRock (BLK), Fate Therapeutics (FATE), Micron Technology (MU), Energy Transfer LP Unit (ET), SCYNEXIS (SCYX), Viking Therapeutics (VKTX) and Gilead Sciences (GILD). Who are Zafgen's key executives? Zafgen's management team includes the folowing people: Mr. Jeffrey S. Hatfield, CEO & Director (Age 61)Ms. Patricia L. Allen, Chief Financial Officer (Age 57)Dr. Dennis D. Kim M.D., MBA, Chief Medical Officer (Age 49)Dr. James E. Vath, Head of Discovery & Devel. (Age 58)Mr. Brian P. McVeigh, Chief Bus. Officer (Age 46) Who are Zafgen's major shareholders? Zafgen's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.74%), FMR LLC (4.10%), Dimensional Fund Advisors LP (2.83%), Renaissance Technologies LLC (2.63%), Northern Trust Corp (0.96%) and Assenagon Asset Management S.A. (0.59%). Company insiders that own Zafgen stock include Dennis D Kim, Frances K Heller and Thomas E Hughes. View Institutional Ownership Trends for Zafgen. Which institutional investors are selling Zafgen stock? ZFGN stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Morgan Stanley, Oxford Asset Management LLP, BlackRock Inc., Northern Trust Corp, New York State Common Retirement Fund and Charles Schwab Investment Management Inc.. View Insider Buying and Selling for Zafgen. Which institutional investors are buying Zafgen stock? ZFGN stock was purchased by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Renaissance Technologies LLC, Dimensional Fund Advisors LP, Acadian Asset Management LLC, JPMorgan Chase & Co., Wedbush Securities Inc., Alambic Investment Management L.P. and Hikari Power Ltd. Company insiders that have bought Zafgen stock in the last two years include Dennis D Kim and Frances K Heller. View Insider Buying and Selling for Zafgen. How do I buy shares of Zafgen? Shares of ZFGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Zafgen's stock price today? One share of ZFGN stock can currently be purchased for approximately $2.49. How big of a company is Zafgen? Zafgen has a market capitalization of $92.95 million. The biopharmaceutical company earns $-61,370,000.00 in net income (profit) each year or ($1.90) on an earnings per share basis. Zafgen employs 38 workers across the globe. What is Zafgen's official website? The official website for Zafgen is http://www.zafgen.com. How can I contact Zafgen? Zafgen's mailing address is 175 PORTLAND STREET 4TH FLOOR, BOSTON MA, 02114. The biopharmaceutical company can be reached via phone at 617-622-4003 or via email at [email protected] MarketBeat Community Rating for Zafgen (NASDAQ ZFGN)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 283 (Vote Outperform)Underperform Votes: 253 (Vote Underperform)Total Votes: 536MarketBeat's community ratings are surveys of what our community members think about Zafgen and other stocks. Vote "Outperform" if you believe ZFGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZFGN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/19/2019 by MarketBeat.com StaffFeatured Article: Put Option Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.